• FDA says children as young as age 3 years can take Epclusa for hepatitis C

    1 day ago - By Healio

    Under an FDA-approved expansion of the pediatric indication, children as young as age 3 years are now able to receive Epclusa for the treatment of chronic hepatitis C virus regardless of HCV genotype or severity.
    The FDA originally approved Epclusa for adults in 2016 and for children aged 6 years or older in March 2020.
    Gilead said the FDA has approved two strengths of an oral pellet - sofosbuvir 200 mg/velpatasvir 50 mg and sofosbuvir 150 mg/velpatasvir 37.5 mg - that were developed for younger children who cannot swallow tablets. The
    Read more ...

     

  • Combination ravidasvir, sofosbuvir effectively treats chronic hepatitis C

    Combination ravidasvir, sofosbuvir effectively treats chronic hepatitis C

    1 day ago - By Healio

    Ravidasvir in addition to sofosbuvir was safe and effective in the treatment of patients with chronic hepatitis C virus, according to research published in The Lancet Gastroenterology and Hepatology.
    “The WHO Global Health Sector Strategy on Viral Hepatitis 2016-21 aims to eliminate viral hepatitis as a public health threat, test 90% of people with HCV and treat 80% of people with HCV worldwide by 2030. However, by March 2021, only 12 countries were on course to HCV elimination by 2030,” Isabelle Andrieux-Meyer, MD, of the Drugs for Neglected Diseases Initiative in Geneva,
    Read more ...